Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Phase 3 clinical trials continue, with approval decisions expected sometime between late 2026 and early 2027
The MOTS-c peptide research is particularly relevant here, as MOTS-c affects mitochondrial function and exercise capacity in ways that could complement the metabolic effects of retatrutide
If these effects translate to humans, GLP-1 medications could theoretically slow neurodegenerative processes
Check your specific product labeling for the beyond-use date
US$ 22.09
US$ 24.53
US$ 27.01
US$ 26.35
US$ 24.40
US$ 22.12
US$ 22.01
